Everest Medicines (HKG: 1952), a leading China-based biotechnology company, has announced two significant appointments to its senior management team. Sandra Zeng has been named Chief Medical Officer, and Rico Liang has been appointed as Chief Product Officer. These strategic hires are set to bolster the company’s drug development and product management capabilities.
Sandra Zeng will lead the clinical development team and drive cross-functional collaborations, with a focus on expediting the progression of Everest Medicines’ in-licensed drug candidates through the clinical development process and towards market launch. Zeng brings a wealth of experience to her new role, with two decades in pharmaceutical discovery, development, and medical affairs in both the US and China. Her resume includes a global program lead position at Bristol-Myers Squibb USA, as well as roles at Celgene Corp., Roche, and Merck, Sharp & Dohme.
Rico Liang, as Chief Product Officer, will oversee the medical affairs and marketing departments, playing a pivotal role in shaping the company’s product strategy and market approach. Liang joins Everest Medicines from his previous position as General Manager of Greater China at Brii Biosciences. His background also includes several commercial roles at prominent pharmaceutical companies such as Gilead China, Roche, Novartis, and Amgen.
These appointments reflect Everest Medicines’ commitment to strengthening its executive team and driving forward its mission to bring innovative medicines to market, addressing significant unmet medical needs.- Flcube.com
